14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYRE vs DNTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas DNTH carries 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin).
Composite vs. Pillar Nuance: While SYRE currently prints a higher short-term Unified Composite Score (36.1/100 SELL vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (3–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. 0.0% operating margin) and revenue trajectory (+205.6% vs. +0.0% YoY).
Defensive Composite Rating Caution: Although DNTH compares more favorably head-to-head, both SYRE (36.1/100 SELL) and DNTH (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs DNTH. Trailing 12-month operating profitability (SYRE 0.0% vs DNTH -8683.9%) and valuation multiples (SYRE N/M vs DNTH N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $5.2B market capitalization and -8683.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SYRE vs DNTH Key Questions & Quantitative Answers
As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas DNTH carries 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin). Composite vs. Pillar Nuance: While SYRE currently prints a higher short-term Unified Composite Score (36.1/100 SELL vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (3–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. 0.0% operating margin) and revenue trajectory (+205.6% vs. +0.0% YoY). Defensive Composite Rating Caution: Although DNTH compares more favorably head-to-head, both SYRE (36.1/100 SELL) and DNTH (34.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
DNTH leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DNTH at +205.6% YoY revenue growth and +0.0% YoY earnings growth on $2.7M TTM revenue (100.0% gross margin, -8683.9% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $2.7M for DNTH. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNTH.
SYRE and DNTH trade at balanced relative valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DNTH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus DNTH (-22.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, DNTH carries 83.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.03β · 41% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.